CIRM Funded Clinical Trials

A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients with Mucopolysaccharidosis Type 1

Disease Area: 
Intellectual Disability
Metabolic Disorders
Investigator:
CIRM Grant:
Award Value:
$8,000,000
Trial Sponsor:
Immusoft Corporation
Trial Stage: 
Phase 1
Trial Status: 
Launching
Targeted Enrollment:
N/A